Mario Negri Institute For Pharmacological Research
Clinical trials sponsored by Mario Negri Institute For Pharmacological Research, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Wearable listens to dialysis veins: could it predict problems? Results expected Sep 2026 (estimated)
- New algorithm aims to improve emergency room admission decisions Results expected Sep 2026 (estimated)
- New tests could transform care for rare kidney diseases Results expected Oct 2026 (estimated)
- Immune cell clues could unlock kidney disease treatment secrets Results expected Nov 2026 (estimated)
- New algorithm aims to reduce unnecessary hospital admissions Results expected Dec 2026 (estimated)
-
Could a leukemia drug help fight breast cancer? new trial investigates
Disease control Stopped earlyThis study tested whether adding a drug called ATRA (all-trans retinoic acid) to the standard hormone therapy anastrozole could shrink tumors more effectively in postmenopausal women with a common type of early breast cancer (HR-positive/HER2-negative). The trial was planned for …
Phase 2 • Sponsor: Mario Negri Institute for Pharmacological Research • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
New combo may help more lung cancer patients get Life-Extending radiation
Disease control Stopped earlyThis study tested whether adding the immunotherapy drug durvalumab to standard chemotherapy could shrink large stage III lung tumors enough to allow patients to then receive radiation therapy. The trial was stopped early after enrolling only 10 people, so results are limited. The…
Phase 2 • Sponsor: Mario Negri Institute for Pharmacological Research • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC